Marina Lubimova
Advisers are proposing a valuation multiple of 15–20 times EBITDA, potentially valuing the company at $66–88 billion. The listing could take place in early 2027, although late 2026 remains possible.
IPO Details
| Parameter | Details |
| Target valuation | At least $66 billion |
| Indicative valuation range | $66–88 billion |
| Valuation multiple | 15–20× EBITDA |
| Listing exchange | Hong Kong |
| Expected timing | Late 2026–early 2027 |
| Potential equity stake | 10–20% |
| Controlling shareholder | Sinochem |
| Advisers | UBS, CICC, China CITIC Bank, Bank of America |
At a $66–88 billion equity valuation, selling 10–20% of the company would imply gross proceeds of approximately $6.6–17.6 billion. The actual offering size has not been confirmed.
Financial Performance
Syngenta reported higher EBITDA in 2025 despite a slight decline in revenue.
| Metric | 2024 | 2025 | Change |
| Revenue | $28.8B | $28.4B | −1% |
| EBITDA | $3.9B | $4.4B | +13% |
| EBITDA margin | 13.5% | 15.4% | +1.9 pp |
| Crop Protection revenue | $13.2B | $13.7B | +4% |
| Seeds revenue | $4.8B | $4.8B | Flat |
H1 2026 results:
- Revenue: $12.2 billion, down 2%.
- EBITDA: $2.4 billion, up 2%.
- EBITDA margin: 19.5%, compared with 18.6% a year earlier.
Comparison With Previous IPO Attempt
| Parameter | Shanghai IPO (2021–2024) | Hong Kong IPO (2026–2027) |
| Target valuation | Approximately $60B | $66–88B |
| Planned fundraising | Approximately $9–10B | Not confirmed |
| Exchange | Shanghai | Hong Kong |
| Status | Withdrawn March 2024 | Under preparation |
The new minimum valuation is approximately 10% higher than the $60 billion figure associated with the previous listing attempt. At $88 billion, the difference reaches 47%.
For historical comparison, ChemChina acquired Syngenta for approximately $43 billion in 2017, although the group's structure has since changed.
Valuation Analysis
Based on Syngenta's 2025 EBITDA of $4.4 billion:
| EBITDA multiple | Implied enterprise value |
| 15× | $66B |
| 17.5× | $77B |
| 20× | $88B |
These are illustrative enterprise values, not confirmed IPO equity valuations. Net debt and other adjustments would affect the equity value.
Outlook
The IPO would provide funding for debt reduction and investment in seeds and crop-protection technologies.
Final valuation and proceeds will depend on 2026 earnings, debt levels, investor demand and market conditions.
Marina Lubimova
